BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
10/28/2021 3:02:02 AM | Browse: 1166 | Download: 2251
Publication Name World Journal of Immunology
Manuscript ID 68033
Country Bulgaria
ISSN 2219-2824 (online)
Open Access This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/
Copyright © The Author(s) 2021. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website http://www.wjgnet.com
Category Transplantation
Manuscript Type Opinion Review
Article Title Interactions between human microbiome, liver diseases, and immunosuppression after liver transplant
Manuscript Source Unsolicited Manuscript
All Author List Milena Peruhova, Monika Peshevska-Sekulovska and Tsvetelina Velikova
ORCID
Author(s) ORCID Number
Milena Peruhova http://orcid.org/0000-0002-6618-2324
Monika Peshevska-Sekulovska http://orcid.org/0000-0002-8468-0132
Tsvetelina Velikova http://orcid.org/0000-0002-0593-1272
Funding Agency and Grant Number
Corresponding Author Milena Peruhova, MD, Assistant Professor, Chief Doctor, Department of Gastroenterology, University Hospital Lozenetz, Kozyak 1 str., Sofia 1407, Bulgaria. mperuhova@gmail.com
Key Words Liver transplantation; De novo malignancy; Immunosuppressive therapy; Calcineurin inhibitors; Tacrolimus; Cyclosporine; Microbiome; Carcinogenesis; Immune tolerance
Core Tip It was estimated that liver transplant recipients have a higher risk of developing de novo malignancy (DNM) compared to the general population. Immunosuppressive (IS) therapy used after liver transplantation (LT) is one of the substantial risk factors for the development of DNM. Tumorigenesis and tumor growth in LT patients are linked with the length of IS therapy's administration and intensity. Recent data showed that the microbiota could significantly affect the survival and acceptance of transplanted allographs. This once again indicates the incredibly complex interaction between the immune system and microbiome in the settings of LT and raises the possible strategies to induce immunotolerance and reduce the complications such as DNM.
Publish Date 2021-10-28 03:02
Citation Peruhova M, Peshevska-Sekulovska M, Velikova T. Interactions between human microbiome, liver diseases, and immunosuppression after liver transplant. World J Immunol 2021; 11(2): 11-16
URL https://www.wjgnet.com/2219-2824/full/v11/i2/11.htm
DOI https://dx.doi.org/10.5411/wji.v11.i2.11
Full Article (PDF) WJI-11-11.pdf
Full Article (Word) WJI-11-11.docx